Sponsor content
60 result(s) found, displaying 1 to 10
-
Dec-2025Prescription medicine evaluationActive ingredient: cabotegravir, rilpivirine.
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
Cancellation by sponsorRequested by ViiV Healthcare Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RUKOBIA fostemsavir (as trometamol) 600 mg extended release tablet bottle.